SCHEMBL17409808

SCHEMBL17409808

COCCN1Cc2cc(C)cnc2C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
ALDH1A1 P00352 7/20 0.33
CYP1A2 P05177 6/20 0.33
HSD17B10 Q99714 4/20 0.33
CYP2C9 P11712 2/20 0.33
TSHR P16473 2/20 0.33
USP2 O75604 2/20 0.32
CYP3A4 P08684 2/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
SYK P43405 1/20 0.31
ALOX15 P16050 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15986726 0.82 KDM4E (0.33) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL21622307 0.81 JAK2 (0.34) ALDH1A1HSD17B10TSHRMAPK1CYP2C19
SCHEMBL21626710 0.79 LMNA (0.32) ALDH1A1LMNAADORA2AADORA1
SCHEMBL26032293 0.75 ALDH1A1 (0.32) KMT2AMEN1ALDH1A1CYP1A2HSD17B10
SCHEMBL14907172 0.75 CCR1 (0.34) CYP1A2CYP2C9CYP2C19
SCHEMBL17409800 0.74 POLB (0.42) KMT2AMEN1ALDH1A1TDP1LMNA
SCHEMBL25975832 0.70 PDCD1 (0.42) CYP3A4CYP2C19LMNAPOLBADORA2A
SCHEMBL14853093 0.69 CYP2C19 (0.45) ALDH1A1HSD17B10CYP2C9TSHRUSP2
SCHEMBL14566143 0.68 CDK4 (0.41) LMNAPOLBADORA2AADORA1CDK1
SCHEMBL14566140 0.68 ADORA2A (0.40) KMT2AMEN1LMNAPOLBADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433622-B2 Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-06 US disclosed
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS TBK1, TBKBP1, TYMS KMT2A 2377/4885MEN1 4342/4885ALDH1A1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.